Radioligand Therapy Market Size Worth USD 36.47 Bn by 2035 AI

Source Domain: www.openpr.com

Market Size and Growth: The global radioligand therapy market is projected to grow significantly from USD 4.08 billion in 2026 to USD 36.47 billion by 2035, with a CAGR of 27.55%.
Key Drivers: Increased cancer cases, particularly prostate and neuroendocrine tumors, continuous advancements in radioligand technologies, and supportive regulatory frameworks drive the growth.
Regional Dominance: North America leads the market with 82% share in 2025 due to advanced healthcare infrastructure and high PET diagnostics adoption. Asia Pacific is expected to be the fastest-growing region.
Market Segments: By product, Lutetium Lu 177 Vipivotide Tetraxetan dominated in 2025. By indication, prostate cancer is the leading segment. By target, prostate-specific membrane antigen (PSMA) is dominant.
Leading Companies: Key players include Novartis AG, Bayer AG, and Eli Lilly and Company, among others, who are investing in manufacturing and therapy development.
Future Prospects: Anticipated growth in Asia-Pacific due to increasing cancer awareness and healthcare investments, and rapid adoption of AI and digital health technologies in cancer treatment.

You may have missed